Prilosec Lawsuit Update 2019: A Comprehensive Overview

In 2019, several significant developments unfolded in the ongoing litigation against Prilosec, a popular proton pump inhibitor (PPI) medication manufactured by AstraZeneca. This article provides a detailed update on the Prilosec lawsuit, focusing on key events, allegations, and their potential impacts.

Understanding Prilosec and PPIs
Prilosec (omeprazole) is a widely prescribed medication used to treat heartburn, ulcers, and other gastrointestinal disorders. It belongs to a class of drugs known as proton pump inhibitors (PPIs), which work by reducing stomach acid production. Other popular PPIs include Nexium, Prevacid, and Protonix.

Allegations Against Prilosec
Plaintiffs in the Prilosec lawsuit allege that AstraZeneca failed to adequately warn patients and healthcare providers about the potential risks associated with long-term use of the drug. Some of the most concerning side effects linked to Prilosec and other PPIs include:

- Chronic kidney disease
- Kidney failure
- Bone fractures
- Low magnesium levels (hypomagnesemia)
- Increased risk of dementia
Key Developments in the Prilosec Lawsuit in 2019
MDL Consolidation

In January 2019, the U.S. Judicial Panel on Multidistrict Litigation (JPML) consolidated all federally filed Prilosec lawsuits into a single multidistrict litigation (MDL) in the U.S. District Court for the District of Minnesota. This move aimed to streamline pretrial proceedings and promote efficiency.
Bellwether Trials
Throughout 2019, several bellwether trials were scheduled and concluded. These trials, involving a small group of representative plaintiffs, help both sides gauge the strength of their arguments and may influence settlement negotiations. Some notable outcomes include:

| Plaintiff | Outcome |
|---|---|
| Linda Hill | Verdict for the defendant (AstraZeneca) |
| John and Diane Henry | Verdict for the plaintiffs, with an award of $1.2 million |
FDA Warnings




















In 2019, the U.S. Food and Drug Administration (FDA) issued new warnings regarding the risks of long-term PPI use. The agency advised that patients taking PPIs for more than three years may be at an increased risk of fractures, and those taking high doses may experience low magnesium levels. AstraZeneca was required to update the Prilosec prescribing information to reflect these warnings.
Looking Ahead: What to Expect in the Prilosec Lawsuit
As of 2020, the Prilosec lawsuit continues to evolve, with more bellwether trials and settlement negotiations anticipated. Plaintiffs and their attorneys remain committed to seeking compensation for the damages they allege were caused by AstraZeneca's failure to warn about Prilosec's risks. As new information becomes available, we will continue to provide updates on the latest developments in the Prilosec lawsuit.